A prior case report revealed that osimertinib, bevacizumab, and brigatinib combination treatment relieved tumor growth and respiratory symptoms in a patient with adenocarcinoma harboring an EGFR L858R/T790M/C797S triple mutation [10]. The gene discussed is EGFR; the disease is neoplasm.